Aktiesnakken — August 2015
-
Dette første studie med daratumumab i mennesker, som er fuldt beskrevet i The New England Journal of Medicine, viste imponerende responsniveau og -varighed, især når man tager højde for, at patienterne i studiet tidligere havde modtaget mange behandlinger," udtaler Jan van de Winkel.
-
Morgen.
-
Der var heller ikke meget at klage på.
-
Hej Karbold.
-
Velkommen till Esketm.
-
Velkommen til tnodland.
-
Velkommen til Canbaz.
-
Børsen på besøg i PI´s redaktions lokaler:
-
-
Velkommen til Thomha..:-)
-
-
Ny Tesla sprænger næsten lydmuren: http://www.bloomberg.com/news/articles/2015-08-27/tesla-with-insane-mode-busts-curve-on-consumer-reports-ratings-idu1hfk0
-
0-100 Km/t på 2,8 sekunder.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind